COVID-19 Spike Protein mRNA(N1-Me-Pseudo UTP)
Based on 1 publication(s) in Google Scholar
COVID-19 Spike Protein mRNA (N1-Me-Pseudo UTP) is an mRNA encoding the SARS-CoV-2 spike protein with enhanced performance via chemical modification. COVID-19 Spike Protein mRNA (N1-Me-Pseudo UTP) replaces natural uridine (UTP) with N1-Me-Pseudo UTP, which effectively reduces immunogenicity and improves stability and translation efficiency. The 3' UTR of COVID-19 Spike Protein mRNA (N1-Me-Pseudo UTP) optimizes AU-rich elements through HuR anchor sites, exhibiting higher translation efficiency. COVID-19 Spike Protein mRNA is widely used in COVID-19-related scientific research and vaccine development.
For research use only. We do not sell to patients.
- Purity : 89%
-
Storage:
-80°C
Publications Citing Use of MedChemExpress (MCE) COVID-19 Spike Protein mRNA(N1-Me-Pseudo UTP)
More
Biological Activity
Description
In Vitro
COVID-19 Spike Protein mRNA (N1-Me-Pseudo UTP) not only contains N1-Me-Pseudo UTP modification, but also mimics the complete structure of natural mRNA, including the 5' Cap 1 cap structure, 5' and 3' untranslated regions (UTR), and 3' poly (A) tail, ensuring efficient expression of the spike protein in human cells. After injection into the human body, COVID-19 Spike Protein mRNA (N1-Me-Pseudo UTP) directs cells to produce the spike protein, thereby safely training the immune system to recognize and attack the authentic SARS-CoV-2 virus, providing strong protection against COVID-19[1].
COVID-19 Spike Protein mRNA (N1-Me-Pseudo UTP) has three key advantages: significantly reduced immunogenicity (avoiding excessive recognition by the human immune system), enhanced molecular stability (prolonging its half-life in vivo), and improved translation efficiency (producing more spike proteins to trigger immune responses)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
Appearance Liquid
-
Color Colorless to light yellow
-
SMILES
[COVID-19 Spike Protein mRNA(N1-Me-Pseudo UTP)]
-
Shipping
Shipping with dry ice.
-
Storage
-80°C
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Trends Biotechnol
2025 Aug 29:S0167-7799(25)00302-6. PMID: 40885665
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
Purity & Documentation
-
Data Sheet (268 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Zhang Y, et al. Lung-Selective Delivery of mRNA-Encoding Anti-MERS-CoV Nanobody Exhibits Neutralizing Activity Both In Vitro and In Vivo. Vaccines (Basel). 2024;12(12):1315. Published 2024 Nov 24. [Content Brief]
[2]. Ma X, et al. Enhancing mRNA translation efficiency by introducing sequence optimized AU-rich elements in 3' UTR via HuR anchorage. Mol Ther Nucleic Acids. 2025;36(2):102485. Published 2025 Feb 12. [Content Brief]
[3]. Li M, et al. An mRNA vaccine against rabies provides strong and durable protection in mice. Front Immunol. 2023;14:1288879. Published 2023 Oct 26. [Content Brief]
[4]. Cheng X, et al. A Synergistic Lipid Nanoparticle Encapsulating mRNA Shingles Vaccine Induces Potent Immune Responses and Protects Guinea Pigs from Viral Challenges. Adv Mater. 2024;36(13):e2310886. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)